share_log

BRIEF-Synlogic And Ginkgo Bioworks Announce Investigational Synthetic Biotic Medicine For The Treatment Of Homocystinuria

reuters ·  Nov 9, 2021 07:08

Nov 9 (Reuters) - Ginkgo Bioworks Holdings Inc DNA.N :

* SYNLOGIC AND GINKGO BIOWORKS ANNOUNCE INVESTIGATIONAL SYNTHETIC BIOTIC MEDICINE FOR THE TREATMENT OF HOMOCYSTINURIA

* SYNLOGIC- COLLABORATION GENERATES CLINICAL CANDIDATE SYNB1353 USING SYNLOGIC'S PROPRIETARY SYNTHETIC BIOTIC PLATFORM AND GINKGO CODEBASE

* SYNLOGIC - EXPECTS TO FILE IND APPLICATION WITH FDA FOR SYNB1353 AND BEGIN CLINICAL DEVELOPMENT IN 2022

Source text for Eikon: ID:nPnmWbYda Further company coverage: DNA.N

((Reuters.Briefs@thomsonreuters.com;;))

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment